H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 010 KRW 0.82% Market Closed
Market Cap: 190.5B KRW
Have any thoughts about
Hana Pharm Co Ltd?
Write Note

Hana Pharm Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hana Pharm Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
H
Hana Pharm Co Ltd
KRX:293480
Income from Continuing Operations
â‚©19.5B
CAGR 3-Years
5%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Income from Continuing Operations
â‚©162.4B
CAGR 3-Years
12%
CAGR 5-Years
30%
CAGR 10-Years
5%
SK Biopharmaceuticals Co Ltd
KRX:326030
Income from Continuing Operations
-â‚©35.4B
CAGR 3-Years
48%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Income from Continuing Operations
â‚©181.6B
CAGR 3-Years
26%
CAGR 5-Years
34%
CAGR 10-Years
16%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Income from Continuing Operations
â‚©10.8B
CAGR 3-Years
167%
CAGR 5-Years
-11%
CAGR 10-Years
-1%
C
Celltrion Pharm Inc
KOSDAQ:068760
Income from Continuing Operations
â‚©16.5B
CAGR 3-Years
-26%
CAGR 5-Years
81%
CAGR 10-Years
16%
No Stocks Found

Hana Pharm Co Ltd
Glance View

Market Cap
190.5B KRW
Industry
Pharmaceuticals

Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Intrinsic Value
18 041.77 KRW
Undervaluation 39%
Intrinsic Value
Price
H

See Also

What is Hana Pharm Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
19.5B KRW

Based on the financial report for Sep 30, 2024, Hana Pharm Co Ltd's Income from Continuing Operations amounts to 19.5B KRW.

What is Hana Pharm Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-8%

Over the last year, the Income from Continuing Operations growth was -18%. The average annual Income from Continuing Operations growth rates for Hana Pharm Co Ltd have been 5% over the past three years , -8% over the past five years .

Back to Top